| Tue, 21 Sep 2021 15:28:34: | AstraZeneca lays out $360M for 'next-gen' manufacturing plant in Dublin
|
| Tue, 21 Sep 2021 14:07:05: | Seagen, Genmab gun for Merck's Keytruda in cervical cancer with accelerated FDA nod for ADC therapy Tivdak
|
| Tue, 21 Sep 2021 13:32:22: | Merck women's health spinoff Organon debuts first awareness campaign, taking on unplanned pregnancy
|
| Tue, 21 Sep 2021 12:43:10: | Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028
|
| Mon, 20 Sep 2021 16:06:30: | Good ad or bad ad? FDA quiz reminds docs about its Bad Ad program to police problematic advertising
|
| Mon, 20 Sep 2021 14:31:22: | Back to consumer: Novartis’ digital chief Betrand Bodson is leaving pharma after helping break ground
|
| Sat, 18 Sep 2021 17:03:24: | Sanofi's 'Flu Shot Friday' campaign teams up with celebrity actress and nurses' group
|
| Fri, 17 Sep 2021 19:02:11: | Horizon partners with MIT for crowdsourced rare disease solutions, narrows to 5 finalists
|
| Fri, 17 Sep 2021 18:29:36: | ESMO: Studies show COVID vaccines effective and safe for cancer patients, but jury still out for one key group
|
| Fri, 17 Sep 2021 12:23:58: | ESMO: Pfizer, Astellas' latest Xtandi survival data may shore up prostate cancer lead over J&J
|
| Fri, 17 Sep 2021 11:40:40: | With new facility and leadership, CDMO Genezen is stepping up to the big leagues
|
| Fri, 17 Sep 2021 09:12:19: | Fierce Pharma Asia—Takeda's lung cancer nod; 4th death in Astellas' gene therapy trial; Everest's mRNA play
|
| Thu, 16 Sep 2021 20:18:29: | Pfizer recalls all Chantix lots nationwide over concerns of cancer-causing impurity
|
| Thu, 16 Sep 2021 18:05:35: | ESMO: Exelixis lays out promising early Cabometyx combo data in prostate cancer, but key discrepancies persist
|
| Thu, 16 Sep 2021 17:27:54: | Social media deliver pitfalls and positives for pharmas engaging cancer community, agency says
|
| Thu, 16 Sep 2021 15:39:49: | ESMO: With Mirati hot on its tail, Amgen's KRAS-targeting Lumakras combo heads into late-stage colorectal cancer testing
|
| Thu, 16 Sep 2021 13:50:39: | Not your grandma's arthritis: Arthritis Foundation's latest campaign focuses on younger demographic
|
| Thu, 16 Sep 2021 13:37:23: | Biogen's Alzheimer's drug Aduhelm slowly gaining steam among prescribing neurologists, study finds
|
| Wed, 15 Sep 2021 22:11:39: | Pharma outreach to LGBTQ community lacking, reveals untapped market beyond HIV and PrEP: survey
|
| Wed, 15 Sep 2021 18:29:25: | As Pfizer's booster AdComm nears, FDA staffers say COVID vaccines are already working as intended
|
| Wed, 15 Sep 2021 17:03:07: | ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy
|
| Wed, 15 Sep 2021 15:28:49: | ALS Ice Bucket Challenge advocacy group calls for speedy FDA approval of Amylyx now-pending drug
|
| Wed, 15 Sep 2021 14:30:40: | ESMO: In unconventional move, Bayer pits genetically driven cancer drug Vitrakvi against Roche's Rozlytrek in adjusted comparison
|
| Wed, 15 Sep 2021 14:13:54: | CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington's intensifying drug-pricing push
|
| Wed, 15 Sep 2021 13:22:31: | Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial
|
